CA2542492A1 — Sulfoximine-substituted pyrimidines as cdk- and/or vegf inhibitors, their production and use as pharmaceutical agents
Assigned to Bayer Intellectual Property GmbH · Expires 2005-04-28 · 21y expired
What this patent protects
The present invention relates to the pyrimidine derivatives of formula (I), wherein Q, R1, R2, R3, R4, R5, X, and m are defined as in the description, for use as inhibitors of cyclin-dependent kinases and VEGF receptor tyrosinkinases. The invention also relates to a method for pr…
USPTO Abstract
The present invention relates to the pyrimidine derivatives of formula (I), wherein Q, R1, R2, R3, R4, R5, X, and m are defined as in the description, for use as inhibitors of cyclin-dependent kinases and VEGF receptor tyrosinkinases. The invention also relates to a method for producing the same and to the use of the inventive pyrimidines as drugs in the treatment of various diseases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.